Levetiracetam monotherapy for elderly patients with epilepsy

Taoufik M. Alsaadi, Suzanne Koopmans, Michelle L Apperson, Sarah E Tomaszewski Farias

Research output: Contribution to journalArticlepeer-review

64 Scopus citations


We retrospectively identified 14 elderly patients with a history of partial seizures who received levetiracetam (LEV) monotherapy. Patients began LEV either as first line therapy (n = 5) or were converted to LEV monotherapy (n = 9) after failing prior antiepileptic medications (AEDs). Thirteen patients continued on LEV monotherapy for at least 6 months. One patient was lost to follow-up. Eight patients (61.5%) became seizure free. Four patients who began LEV as a first line therapy became seizure free, whereas the remaining four patients who converted to LEV after they failed their previous AEDs became seizure free. Four patients (30.7%) had more than a 50% seizure reduction of seizures. Only one patient had no significant change in seizure frequency after started on LEV. The total dosages used to control seizures were 500-3000 mg/day, (mean 1839.2 mg/day). LEV monotherapy can be effective and well tolerated in this group of patients. A prospective, larger, double blind monotherapy study is needed to confirm this finding.

Original languageEnglish (US)
Pages (from-to)58-60
Number of pages3
Issue number1
StatePublished - Jan 2004


  • Elderly
  • Levetiracetam
  • Monotherapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Neurology
  • Psychology(all)


Dive into the research topics of 'Levetiracetam monotherapy for elderly patients with epilepsy'. Together they form a unique fingerprint.

Cite this